share_log

Sailong Pharmaceutical GroupLtd (SZSE:002898) Swells 27% This Week, Taking Three-year Gains to 45%

Sailong Pharmaceutical GroupLtd (SZSE:002898) Swells 27% This Week, Taking Three-year Gains to 45%

赛龙药业集团有限公司(SZSE:002898)本周上涨27%,使三年涨幅达到45%
Simply Wall St ·  03/15 21:29

Sailong Pharmaceutical Group Co.,Ltd. (SZSE:002898) shareholders might be concerned after seeing the share price drop 11% in the last quarter. But don't let that distract from the very nice return generated over three years. After all, the share price is up a market-beating 45% in that time.

赛龙药业集团有限公司, Ltd.(深圳证券交易所:002898)股东在看到上个季度股价下跌11%后可能会感到担忧。但是,不要让这分散人们对三年来产生的非常可观的回报的注意力。毕竟,在那段时间内,股价上涨了超过市场的45%。

Since the stock has added CN¥461m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.

由于该股仅在过去一周就增加了4.61亿元人民币,因此让我们看看基础表现是否推动了长期回报。

Given that Sailong Pharmaceutical GroupLtd didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

鉴于赛龙制药集团有限公司在过去十二个月中没有盈利,我们将专注于收入增长,以快速了解其业务发展。当一家公司没有盈利时,我们通常预计收入会有良好的增长。可以想象,收入的快速增长如果持续下去,通常会带来利润的快速增长。

Sailong Pharmaceutical GroupLtd's revenue trended up 23% each year over three years. That's much better than most loss-making companies. The share price rise of 13% per year throughout that time is nice to see, and given the revenue growth, that gain seems somewhat justified. If that's the case, now might be the time to take a close look at Sailong Pharmaceutical GroupLtd. If the company is trending towards profitability then it could be very interesting.

赛龙制药集团有限公司的收入在三年内每年增长23%。这比大多数亏损的公司要好得多。在此期间,股价每年上涨13%,这令人欣慰,考虑到收入的增长,这种增长似乎有些合理。如果是这样的话,现在可能是仔细研究赛龙制药集团有限公司的时候了。如果公司倾向于盈利,那可能会很有趣。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以在下面看到收入和收入如何随着时间的推移而变化(点击图片了解确切的值)。

earnings-and-revenue-growth
SZSE:002898 Earnings and Revenue Growth March 16th 2024
SZSE: 002898 2024 年 3 月 16 日收益和收入增长

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

您可以在这张免费的交互式图片中看到其资产负债表如何随着时间的推移而增强(或减弱)。

A Different Perspective

不同的视角

We're pleased to report that Sailong Pharmaceutical GroupLtd shareholders have received a total shareholder return of 12% over one year. There's no doubt those recent returns are much better than the TSR loss of 3% per year over five years. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 1 warning sign we've spotted with Sailong Pharmaceutical GroupLtd .

我们很高兴地报告,赛龙制药集团有限公司的股东在一年内获得了12%的总股东回报率。毫无疑问,最近的回报远好于五年内每年3%的股东总回报率损失。长期亏损使我们保持谨慎,但短期股东总回报率的增长无疑暗示着更光明的未来。尽管市场状况可能对股价产生的不同影响值得考虑,但还有其他因素更为重要。为此,你应该注意我们在赛龙制药集团有限公司发现的1个警告信号。

We will like Sailong Pharmaceutical GroupLtd better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

如果我们看到一些重大的内幕收购,我们会更喜欢赛龙药业集团有限公司。在我们等待的同时,请查看这份免费清单,列出了最近有大量内幕收购的成长型公司。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发